Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA

Pathobiology

Volumn 71, Issue 3, 2004, Pages 123-128

  Rittierodt, Marion ^a   Tschernig, Thomas ^a   Harada, Kunyu ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Department of Neurosurgery   (Japan)

Author keywords

Antisense treatment; Endothelial cell line; Glioblastoma; MDR 1 gene; Multidrug resistance; Oligonucleotides; P glycoprotein

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG RETENTION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN;

CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GLIOBLASTOMA; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; RNA, MESSENGER;

EID: 1842508241     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076466     Document Type: Article

References (47)

1. Choi KH, Chen CJ, Kriegler M, Roninson IB: An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988;53:519-529.
2. Orlowski S, Garrigos M: Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res 1999;19:3100-3124.
3. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
4. Simon SM, Schindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-3504.
5. Bradley G, Juranka PF, Ling V: Mechanisms of multidrug resistance. Biochim Biophys Acta 1988;948:87-128.
6. Ruetz S, Gros P: Functional expression of Pglycoproteins in secretory vesicles. J Biol Chem 1994;269:12277-12284.
7. Fardel O, Lecureur V, Daval S, Corlu A, Guilouzo A: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 1997;246:186-192.
8. Isobe H, Wellham L, Sauerteig A, Sridhar KS, Ramachandran C, Krishan A: Doxorubicin retention and chemoresistance in human mesothelioma cell lines. Int J Cancer 1994;57:581-585.
9. Bennis S, Faure P, Chapey C, Hu YP, Fourche J, El Yamani J, Robert J: Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin. Anticancer Drugs1997;8:610-617.
10. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
11. Abe T, Koike K, Ohga T, Kubo T, Wada M, Kohno K, Mori T, Hidaka K, Kuwano M: Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br J Cancer 1995;72:418-423.
12. Dalton WS, Crowley JJ, Salmon S, Grogan TM, Rodgers Laufman L, Weiss GR, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. Cancer 1995;75:815-820.
13. Haux J: Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses 1999;53:543-548.
14. Rittierodt M, Harada K: Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression - A special role for endothelial cells. Exp Toxicol Pathol 2003, in press.
15. Alama A, Barbieri F, Cagnoli M, Schettini G: Antisense oligonucleotides as therapeutic agents. Pharmacol Res 1997;36:171-178.
16. Agrawal S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1999;1489:53-68.
17. Stein CA: Two problems in antisense biotechnology: In vitro delivery and the design of antisense experiments. Biochim Biophys Acta 1999;1489:45-52.
18. Xu DG, Nordlund TM: Sequence dependence of energy transfer in DNA oligonucleotides. Biophys J 2000;78:1042-1058.
19. Biedler LJ: Genetic aspects of multidrug resistance. Cancer 1992;70(suppl):1799-1809.
20. Borst P: Genetic mechanisms of drug resistance. A review. Acta Oncol 1991;30:87-105.
21. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB: Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989;9:3808-3820.
22. Ramachandran C, Melnick SJ: Multidrug resistance in human tumors - Molecular diagnosis and clinical significance. Mol Diagn 1999;4:81-94.
23. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS: P-glycoproteins in pathology: The multidrug resistance gene family in humans. Hum Pathol 1990;21:34-48.
24. Furuya KN, Bradley G, Sun D, Schuetz EG, Schuetz JD: Identification of a new P-glycoprotein-like ATP-binding cassette transporter gene that is overexpressed during hepatocarcinogenesis. Cancer Res 1997;57:3708-3716.
25. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P: Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995;34:32-39.
26. van Veen HW, Konings WN: The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta 1998;1365:31-36.
27. Cordon-Cardo C, O'Brien JP, Casals D, Rittmann-Grauer L, Biedler JL, Melamed MR, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-698.
28. Schumacher U, Mollgard K: The multidrugresistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain. Histochem Cell Biol 1997;108:179-182.
29. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori S: Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 1998;40:11-18.
30. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug-resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-1287.
31. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Paston I: Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
32. von Bossanyi P, Diete S, Dietzmann K, Warich-Kirches M, Kirches E: Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 1997;94:605-611.
33. Fenart L, Buee-Scherrer V, Descamps L, Duhem C, Poullain MG, Cecchelli R, Dehouck MP: Inhibition of P-glycoprotein: Rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier. Pharm Res 1998;15:993-1000.
34. Goldstein GW: The blood-brain barrier: Interacters between endothelial cells and astrocytes. Mead Johnson Symp Perinat Dev Med 1987;29:15-17.
35. Stanness KA, Westrum LE, Fornaciari E, Mascagni P, Nelson JA, Stenglein SG, Myers T, Janigro D: Morphological and functional characterization of an in vitro blood-brain barrier model. Brain Res 1997;771:329-342.
36. Hegmann EJ, Bauer HC, Kerbel RS: Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res 1992;52:6969-6975.
37. Hurwitz AA, Berman JW, Rashbaum WK, Lyman WD: Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells. Brain Res 1993;625:238-243.
38. Rubin LL, Staddon JM: The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28.
39. Sakata A, Tamai I, Kawazu K, Deguchi Y, Ohnishi T, Saheki A, Tsuji A: In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the bloodbrain barrier. Biochem Pharmacol 1994;48:1989-1992.
40. Tsuji A, Tamai I, Sakata A, Tenda Y, Terasaki T: Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 1993;46:1096-1099.
41. Sawada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M: Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol 1999;16:23-27.
42. Diesbach P, Berens C, N'Kuli F, Monsigny M, Sonveaux E, Wattiez R, Courtoy PJ: Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HegG2 cells. Nucleic Acids Res 2000;28:868-874.
43. Cohen JS: Oligonucleotides as therapeutic agents. Pharmacol Ther 1991;52:211-255.
44. Crooke ST: Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999;1489:31-44.
45. Agrawal I, Kandimalla ER: Antisense therapeutics: Is it as simple as complementary base recognition? Mol Med Today 2000;6:72-81.
46. Baker BF, Monia BP: Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta 1999;1489:3-18.
47. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989;86:3474-3478.